Financial Performance - Q1 2025 - Total revenue reached $265 million, a 35% increase compared to the same period last year[9] - Royalty revenue increased by 39% to $168 million[9] - GAAP net income was $118 million, a 54% increase[9] - GAAP diluted EPS increased by 55% to $0.93, while non-GAAP diluted EPS increased by 41% to $1.11[9] - Adjusted EBITDA increased by 40% to $162 million[9] Key Products & Growth Drivers - DARZALEX® SC U S market share is approximately 95%[11] - DARZALEX® sales reached $3.2 billion in Q1 2025, a 22% year-over-year increase[12] - Phesgo® sales are projected to reach $3.3 billion in 2028[14], with Q1 2025 revenue at approximately $675 million, a 52% year-over-year increase[15] - VYVGART® & VYVGART® Hytrulo SC are projected for blockbuster growth to approximately $7 billion in 2028[18] Financial Outlook & Capital Allocation - The company announced a new $250 million share repurchase program[10, 37] - The company projects approximately $1 billion of royalty revenue in 2027[31] - Total revenue for 2025 is guided between $1200 million and $1280 million[40]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative solutions [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [3] - Halozyme has impacted over one million patients through its technology, which is used in ten commercialized products across more than 100 global markets [3] Product Development - Halozyme develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies to enhance convenience, reliability, and patient comfort [4] - The company has two proprietary commercial products: Hylenex® and XYOSTED®, along with partnered products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Financial Results - Halozyme will release its first quarter 2025 financial and operating results on May 6, 2025, after the market closes [1] - A conference call to discuss these results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, with live access available through pre-registration [1][2]